Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedApr 22, 2024
DataAggregated Company Financials
Companies20
  • 7D-1.5%
  • 3M18.6%
  • 1Y39.8%
  • YTD21.9%

Over the last 7 days, the Healthcare industry has dropped 1.5%, driven by Genmab declining 2.4%. This takes the industry's 12 month performance to a gain of 40%. Looking forward, earnings are forecast to grow by 15% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 24 Apr 2024kr.4.4tkr.341.3bkr.99.6b33.3x44.5x13x
Fri, 22 Mar 2024kr.4.6tkr.341.2bkr.99.6b39.4x46x13.4x
Sun, 18 Feb 2024kr.4.4tkr.340.0bkr.98.7b34.9x44.3x12.9x
Tue, 16 Jan 2024kr.3.8tkr.320.5bkr.90.0b33.5x41.9x11.8x
Thu, 14 Dec 2023kr.3.5tkr.320.5bkr.90.0b32.3x38.9x10.9x
Sat, 11 Nov 2023kr.3.6tkr.319.8bkr.89.9b31.6x39.6x11.1x
Mon, 09 Oct 2023kr.3.4tkr.305.5bkr.82.2b33.2x41.4x11.1x
Wed, 06 Sep 2023kr.3.5tkr.305.4bkr.82.2b36.8x42.6x11.5x
Fri, 04 Aug 2023kr.2.9tkr.288.2bkr.74.9b38.6x39.1x10.2x
Sun, 02 Jul 2023kr.3.0tkr.287.1bkr.75.5b40.3x39.9x10.5x
Tue, 30 May 2023kr.3.1tkr.287.1bkr.75.5b41.8x41.4x10.9x
Thu, 27 Apr 2023kr.3.1tkr.272.6bkr.68.5b44x44.9x11.3x
Sat, 25 Mar 2023kr.2.9tkr.291.2bkr.69.0b36.7x42.1x10x
Mon, 20 Feb 2023kr.2.8tkr.289.4bkr.68.9b40x40.4x9.6x
Wed, 18 Jan 2023kr.2.7tkr.276.0bkr.66.3b38.2x40.9x9.8x
Fri, 16 Dec 2022kr.2.7tkr.276.1bkr.66.3b38.4x40.5x9.7x
Sun, 13 Nov 2022kr.2.4tkr.276.0bkr.66.6b35x36x8.7x
Tue, 11 Oct 2022kr.2.3tkr.261.4bkr.62.4b33.3x36.9x8.8x
Thu, 08 Sep 2022kr.2.3tkr.261.2bkr.62.4b35x37.4x8.9x
Sat, 06 Aug 2022kr.2.3tkr.256.0bkr.61.1b33.9x37.6x9x
Mon, 04 Jul 2022kr.2.3tkr.247.7bkr.59.9b36.1x39x9.4x
Wed, 01 Jun 2022kr.2.3tkr.247.5bkr.59.7b35.3x38.5x9.3x
Fri, 29 Apr 2022kr.2.4tkr.238.2bkr.59.8b36.7x39.4x9.9x
Sun, 27 Mar 2022kr.2.2tkr.238.0bkr.59.8b39x37.4x9.4x
Tue, 22 Feb 2022kr.2.0tkr.237.5bkr.59.4b38.1x34.4x8.6x
Thu, 20 Jan 2022kr.2.1tkr.229.2bkr.57.8b47.5x36.3x9.2x
Sat, 18 Dec 2021kr.2.4tkr.229.2bkr.57.8b51.2x42.1x10.6x
Mon, 15 Nov 2021kr.2.4tkr.229.1bkr.57.8b54.8x42x10.6x
Wed, 13 Oct 2021kr.2.1tkr.223.3bkr.55.6b59.7x38.2x9.5x
Fri, 10 Sep 2021kr.2.2tkr.223.2bkr.55.6b64.8x39.5x9.9x
Sun, 08 Aug 2021kr.2.2tkr.223.2bkr.55.6b65.9x40.1x10x
Sat, 01 May 2021kr.1.8tkr.221.0bkr.56.6b45x31.4x8x
Price to Earnings Ratio

31.4x


Total Market Cap: kr.1.8tTotal Earnings: kr.56.6bTotal Revenue: kr.221.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 39.6x202220232024
Current Industry PE
  • Investors are optimistic on the Danish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 44.5x which is higher than its 3-year average PE of 39.6x.
  • The 3-year average PS ratio of 10.1x is lower than the industry's current PS ratio of 13.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 21% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.41%
Healthcare-1.52%
Healthcare Services-1.07%
Medical Equipment-1.21%
Pharma-1.49%
Healthtech-2.28%
Biotech-2.48%
Life Sciences-3.46%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 84.5x.
    • Analysts are expecting annual earnings growth of 61.0% and investors are willing to pay a premium for that growth.
  • Investors are most pessimistic about the Healthcare Services industry, which is trading close to its 3-year average of 17.6x.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 61% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo Nordiskkr.891.302.7%
+kr.106.0b		54.4%PE47.5x
DEMANT Demantkr.322.801.7%
+kr.1.2b		13.2%PE27.5x
EMBLA Embla Medical hfkr.30.703.0%
+kr.384.2m		-0.2%PE33x
ZEAL Zealand Pharmakr.611.001.0%
+kr.373.6m		152.7%PS111x
COLO B Coloplastkr.916.600.2%
+kr.314.7m		-4.9%PE42.3x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

EMBLA

kr.30.70

Embla Medical hf

7D

3.0%

1Y

-0.2%

NNIT

kr.109.00

NNIT

7D

-0.2%

1Y

63.9%

CHEMM

kr.291.20

ChemoMetec

7D

-5.8%

1Y

-16.6%

NOVO B

kr.891.30

Novo Nordisk

7D

2.7%

1Y

54.4%

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

BIOPOR

kr.1.23

BioPorto

7D

-2.8%

1Y

-19.7%

BAVA

kr.151.10

Bavarian Nordic

7D

-0.7%

1Y

-19.9%

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09
Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

COLO B

kr.916.60

Coloplast

7D

0.2%

1Y

-4.9%

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Apr 08
There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

AMBU B

kr.112.05

Ambu

7D

0.2%

1Y

7.2%

Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity

Apr 06
Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity

GMAB

kr.2,008.00

Genmab

7D

-2.4%

1Y

-28.9%

SMSMED

kr.7.42

Scandinavian Medical Solutions

7D

-4.1%

1Y

-30.3%

ZEAL

kr.611.00

Zealand Pharma

7D

1.0%

1Y

152.7%

DEMANT

kr.322.80

Demant

7D

1.7%

1Y

13.2%

Is Now An Opportune Moment To Examine Demant A/S (CPH:DEMANT)?

Mar 18
Is Now An Opportune Moment To Examine Demant A/S (CPH:DEMANT)?

GUBRA

kr.293.00

Gubra

7D

5.0%

1Y

175.9%

Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%

Mar 07
Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%

ALK B

kr.128.70

ALK-Abelló

7D

1.1%

1Y

52.5%

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

BRAINP

kr.0.13

Brain+

7D

-5.1%

1Y

-79.7%